Krahling V, Erbar S, Kupke A, Nogueira S, Walzer K, Berger H
Mol Ther. 2022; 31(2):374-386.
PMID: 36303436
PMC: 9931551.
DOI: 10.1016/j.ymthe.2022.10.011.
Kupke A, Volz A, Dietzel E, Freudenstein A, Schmidt J, Shams-Eldin H
Vaccines (Basel). 2022; 10(4).
PMID: 35455282
PMC: 9027530.
DOI: 10.3390/vaccines10040533.
Jarahian M, Marstaller K, Banna N, Ahani R, Etemadzadeh M, Boller L
J Innate Immun. 2021; 14(2):135-147.
PMID: 34425576
PMC: 9082198.
DOI: 10.1159/000517628.
Sohrabi F, Saeidifard S, Ghasemi M, Asadishad T, Hamidi S, Hosseini S
Eur Phys J Plus. 2021; 136(6):675.
PMID: 34178567
PMC: 8214556.
DOI: 10.1140/epjp/s13360-021-01657-9.
Yu Z, Wu H, Huang Q, Zhong Z
J Clin Lab Anal. 2021; 35(6):e23786.
PMID: 33939238
PMC: 8183904.
DOI: 10.1002/jcla.23786.
Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity.
Flego M, Frau A, Accardi L, Mallano A, Ascione A, Gellini M
BMC Biotechnol. 2019; 19(1):64.
PMID: 31488108
PMC: 6727353.
DOI: 10.1186/s12896-019-0554-2.
Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone.
Liu Y, Sun Y, Wu W, Li A, Yang X, Zhang S
Virol Sin. 2018; 33(4):323-334.
PMID: 30066045
PMC: 6178096.
DOI: 10.1007/s12250-018-0044-z.
Strategies in Ebola virus disease (EVD) diagnostics at the point of care.
Coarsey C, Esiobu N, Narayanan R, Pavlovic M, Shafiee H, Asghar W
Crit Rev Microbiol. 2017; 43(6):779-798.
PMID: 28440096
PMC: 5653233.
DOI: 10.1080/1040841X.2017.1313814.
Diagnosis of Ebola Virus Disease: Past, Present, and Future.
Broadhurst M, Brooks T, Pollock N
Clin Microbiol Rev. 2016; 29(4):773-93.
PMID: 27413095
PMC: 5010747.
DOI: 10.1128/CMR.00003-16.
Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.
Krahling V, Becker D, Rohde C, Eickmann M, Eroglu Y, Herwig A
Med Microbiol Immunol. 2015; 205(2):173-83.
PMID: 26475282
DOI: 10.1007/s00430-015-0438-6.
Ebola virus: a clear and present danger.
Burd E
J Clin Microbiol. 2014; 53(1):4-8.
PMID: 25392362
PMC: 4290962.
DOI: 10.1128/JCM.03115-14.
Analysis of determinants in filovirus glycoproteins required for tetherin antagonism.
Gnirss K, Fiedler M, Kramer-Kuhl A, Bolduan S, Mittler E, Becker S
Viruses. 2014; 6(4):1654-71.
PMID: 24721789
PMC: 4014715.
DOI: 10.3390/v6041654.
Ebolavirus nucleoprotein C-termini potently attract single domain antibodies enabling monoclonal affinity reagent sandwich assay (MARSA) formulation.
Sherwood L, Hayhurst A
PLoS One. 2013; 8(4):e61232.
PMID: 23577211
PMC: 3618483.
DOI: 10.1371/journal.pone.0061232.
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection.
Qiu X, Fernando L, Melito P, Audet J, Feldmann H, Kobinger G
PLoS Negl Trop Dis. 2012; 6(3):e1575.
PMID: 22448295
PMC: 3308939.
DOI: 10.1371/journal.pntd.0001575.
Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins.
Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky S, Retterer C
J Virol Methods. 2011; 174(1-2):99-109.
PMID: 21513741
PMC: 3106979.
DOI: 10.1016/j.jviromet.2011.04.003.
Laboratory detection and diagnosis of filoviruses.
Wang Y, Zhang X, Wei H
Virol Sin. 2011; 26(2):73-80.
PMID: 21468930
PMC: 8222480.
DOI: 10.1007/s12250-011-3186-9.
The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.
Marzi A, Akhavan A, Simmons G, Gramberg T, Hofmann H, Bates P
J Virol. 2006; 80(13):6305-17.
PMID: 16775318
PMC: 1488929.
DOI: 10.1128/JVI.02545-05.
Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins.
Saijo M, Niikura M, Ikegami T, Kurane I, Kurata T, Morikawa S
Clin Vaccine Immunol. 2006; 13(4):444-51.
PMID: 16603611
PMC: 1459631.
DOI: 10.1128/CVI.13.4.444-451.2006.